| abstract |
The present invention comprises three adjacent segments N, L and C represented by the formula NLC, wherein the N-helical region N of gp41, the C-helical region C of gp41, and the N- (L) comprising a synthetic linker located in the nucleotide sequence of SEQ ID NO: 1, wherein the linker is in a numbering system based on a prototypic HIV-1 HxB2 Clade B isolate Thus replacing amino acids 593 to 617 of gp41, which polypeptide contains a 98.6 D epitope to neutralize calveolin-1 but does not contain 2F5 and 4E10 epitopes, fusion peptides, and the polypeptide Is characterized in that it has minimal immunological cross-reactivity with human interleukin-2 (IL-2). |